35 results on '"Junge, Candice"'
Search Results
2. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
3. Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
4. ATXN7-Related Cone-Rod Dystrophy
5. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
6. Butyrylcholinesterase Kalow variant reduces age‐of‐onset of Alzheimer Disease in apolipoprotein ɛ4 carriers
7. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease
8. Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
9. The Contribution of Protease-Activated Receptor 1 to Neuronal Damage Caused by Transient Focal Cerebral Ischemia
10. The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34+ Cell Administration in Patients With Refractory Angina
11. sj-pdf-2-jcn-10.1177_08830738231152658 - Supplemental material for Pelizaeus-Merzbacher Disease: A Caregiver Assessment of Disease Impact
12. sj-docx-1-jcn-10.1177_08830738231152658 - Supplemental material for Pelizaeus-Merzbacher Disease: A Caregiver Assessment of Disease Impact
13. Pelizaeus-Merzbacher Disease: A Caregiver Assessment of Disease Impact
14. Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: An analysis from ACT34-CMI
15. PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI
16. The Serine Protease Plasmin Cleaves the Amino-terminal Domain of the NR2A Subunit to Relieve Zinc Inhibition of the N-Methyl-d-aspartate Receptors
17. Plasmin Potentiates Synaptic N-Methyl-D-aspartate Receptor Function in Hippocampal Neurons through Activation of Protease-activated Receptor-1
18. Tau-targeting antisense oligonucleotide MAPTRxin mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
19. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: Design of the RENEW study
20. Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes
21. Activation of protease activated receptor 1 increases the excitability of the dentate granule neurons of hippocampus
22. PreSERVE-AMI
23. Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study
24. The RENEW Trial
25. Author Correction: Tau-targeting antisense oligonucleotide MAPTRxin mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
26. Abstract 12754: Infused CD34 Cell Dose, not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients With Left Ventricular Dysfunction post STEMI: Results of the PreSERVE-AMI Trial
27. ONE YEAR FOLLOW-UP RESULTS FROM PRESERVE-AMI: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF INTRACORONARY INFUSION OF AUTOLOGOUS CD34+ CELLS IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION POST STEMI
28. Abstract 1274: SLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancers.
29. IMPACT OF MOBILIZATION ABILITY ON CELL FUNCTIONALITY AND COMPARISON OF NORMAL AND CMI SUBJECT SAMPLES: AN ANALYSIS FROM ACT34–CMI
30. ELECTROMECHANICAL ASSESSMENT OF MYOCARDIAL FUNCTION (NOGA) IS ASSOCIATED WITH EXERCISE IMPROVEMENT IN PATIENTS TREATED WITH AUTOLOGOUS STEM CELL THERAPY FOR REFRACTORY ANGINA
31. Results of the first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with...
32. Autologous CD34+Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study
33. Potentiation of NMDA Receptor Function by the Serine Protease Thrombin
34. A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia.
35. Autologous CD34 + Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.